Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A 2025 study used defocused spatially-offset Raman spectroscopy (SORS) to observe experimental drug-releasing implants beneath ex vivo porcine skin. The laser-based method tracked implant formation and release without labels, while high-performance liquid chromatography (HPLC) measured drug in the surrounding fluid. The results show a research technique—not a proven way to monitor implants in patients.
How the laser technique monitors an implant
Raman spectroscopy detects molecular vibrational signals. In spatially-offset Raman spectroscopy, the light-collection point is displaced from the laser’s illumination point, helping capture information from below the surface. The 2025 study used a defocused SORS arrangement to observe an in situ forming implant (ISFI)—a formulation that forms an implant after administration—in an experimental skin setup. The method did not use labels to track the model drugs. The study record describes the approach as non-invasive and real-time in that model.
The experiment combined full-thickness pig skin with a custom flow-through diffusion cell. SORS measured the implant beneath the skin, while HPLC quantified drug that had entered the receptor medium. The researchers also used confocal Raman microscopy to image cross-sections and check the SORS observations, and compared flow-through results with static Franz diffusion-cell experiments. These measurements provide complementary views: SORS observes the implant, while HPLC quantifies drug released into the fluid.
What the two model drugs revealed
The researchers tested hydrophilic 4-cyanophenol (4-CP) and hydrophobic all-trans retinoic acid (RA). Their release differed sharply under the study’s experimental conditions:
#1 Best Overall
| Model drug | Released after 2.5 days, static condition | Released after 2.5 days, flow-through condition |
|---|---|---|
| Hydrophilic 4-cyanophenol (4-CP) | 90.7% | 94.8% |
| Hydrophobic all-trans retinoic acid (RA) | 3.3% | 2.1% |
These percentages are results for the study’s model formulations and test conditions, not typical rates for other implants or estimates of what a patient would receive. In the paper’s interpretation, the observations linked implant formation with drug release; solvent exchange was a key driver of the pronounced early release seen with 4-CP. The RA results, by contrast, showed much lower release during the same 2.5-day period. Rath and colleagues’ 2025 paper reports the experiment and its measurements.
What the findings establish—and what they do not
The work demonstrates a way to characterize implant formation and model-drug release in an ex vivo skin system by combining Raman measurements with chemical quantification. It does not establish that SORS can routinely measure drug levels through the skin of a living person, improve treatment decisions, or serve as a clinically validated monitoring device. The authors discuss formulation development and individualized therapeutic drug monitoring as potential applications; these remain translational possibilities rather than demonstrated clinical uses.
Rank #2
- Used Book in Good Condition
It is also important to distinguish observing release from triggering it. SORS was used to observe a process; it was not used to control the drug’s release. A separate 2021 study investigated pulsed near-infrared light to trigger release from a purpose-designed ocular PLGA capsule containing light-activated liposomes. That was a different technology and study, not a feature of the 2025 skin experiment. The ocular-implant study describes that separate approach.
How SORS fits alongside other implant-imaging research
Other studies have investigated different ways to examine drug distribution or release. They are separate experiments, not direct head-to-head comparisons with SORS:
Rank #3
- MALDI molecular imaging: A 2022 paper used matrix-assisted laser desorption/ionization (MALDI) mass-spectrometry imaging to map active pharmaceutical ingredient distribution in non-conductive long-acting implants and study release. Read the paper record.
- MALDI-TOF imaging: A 2012 study used this method on controlled-release lipid implants and reported drug-rich regions and concentration gradients. Read the paper record.
- UV-visible imaging: A 2020 study examined early leuprolide release and implant formation in laboratory matrices designed to emulate the subcutaneous environment. Read the paper record.
These approaches differ in the signal they measure and the models they examine. The SORS study’s distinctive contribution is observing an implant beneath ex vivo skin while separately quantifying drug released into fluid. The cited studies do not establish that one method is superior: a fair comparison would need to account for chemical information, real-time measurement, whether samples must be sectioned, model type, preparation requirements, and whether a technique observes release or triggers it.
Quick Recap
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
